Antimicrobial stewardship is a key strategy to combat the emergence of drug resistance.
The key to better health could be solved by taking a closer look at who distributes antibiotics, according to a recent Duke study, reported by Grace Lee, MD, in The Chronicle, a Duke University publication.
The study was conducted in four community hospitals across North Carolina and tested the feasibility of two strategies in lowering the rates of antibiotic over-prescription, a major cause of the development of multidrug-resistant superbugs. The national implementation of these antimicrobial strategies could have wide-ranging benefits, she writes.
“[The issue of multidrug-resistant pathogens] is extraordinarily important. The World Health Organization calls drug resistance one of the three biggest challenges in the 21st century,” says Deverick Anderson, director of the Duke Center for Antimicrobial Stewardship and Infection Prevention and lead author of the study.
The study focused on testing the feasibility of two antimicrobial stewardship strategies recommended by the Infectious Diseases Society of America as well as conducting preauthorization and post-prescription audit and review. In both strategies, pharmacists oversaw the prescription of antibiotics by community hospitals involved in the study, Anderson says.
It was conducted between October 2014 and October 2015 in a three-stage process including 2,692 total patients.
For the first strategy-dubbed preauthorization-doctors were required to receive approval from pharmacists in order to prescribe a certain antibiotic. In the post-prescription audit and review strategy, pharmacists measured the appropriateness of the prescribed antibiotic after three days.
Related:Drug Shortages Continue To Burden Healthcare
Strict preauthorization proved to be an unviable strategy, so Anderson and his team opted for a modification. The modified strategy involved a pharmacist review of the antibiotic prescription following the first dose of the prescribed antibiotic.
Although the modified preauthorization interventions proved relatively ineffective in lowering antibiotic use, post-prescription interventions were a “feasible and effective strategy” in generating a “downtick in antibiotic use,” Anderson says.
Ultimately, post-prescription interventions found inappropriate antibiotic use two times as often as in preauthorization interventions.
“While our goal on the infection prevention side is to have zero infections, there’s no way that we’ll have zero antibiotic use,” Anderson says. “The idea is how best to optimize the antibiotics that we use.”
Support for the study came from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, the CDC, and the Agency for Healthcare Research and Quality.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More